Barcelona Liver Bioservices (BLB), CRO specialized in liver diseases, announced today the publication of the manuscript entitled “New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease” in the peer-reviewed journal Cells. The manuscript describes BLB’s proprietary model of non-alcoholic steatohepatitis, termed BarNa Model®.
“It is recognized that NASH-derived cirrhosis is a burden of disease in our Society, with no therapeutic option available. Considering that no pre-clinical model properly mimics the human pathobiology of the disease, we at BLB invested significant efforts to develop a novel model of advanced NASH in rats that fulfil major clinical characteristics (including steatosis, inflammation, advanced fibrosis and portal hypertension) and shares a significant part of molecular pathways involved in the human disease” affirmed Dr Jordi Gracia-Sancho, CEO & CSO of BLB.
This new and unique model of advanced NASH can be used to test new drug entities designed to treat NAFLD and NASH, and to understand their underlying mechanisms of action, in a complex biological system with marked similarities with the human disease.
BarNa® animals are now available to current and future BLB’s partners, just get in touch with us to start a new research endeavor in the field of metabolic liver diseases.
View full article
Barcelona Liver Bioservices is a CRO focused on the design and development of pre-clinical research in the field of Hepatology. The company offers cutting-edge research services and consulting to foster the development of new therapeutics for liver diseases, including non-alcoholic steatohepatitis and cirrhosis.